Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES LANTMÄNNEN IN CONNECTION WITH ISSUE OF PARTICIPATING DEBENTURES
Mandate

VINGE ADVISES LANTMÄNNEN IN CONNECTION WITH ISSUE OF PARTICIPATING DEBENTURES

November 14, 2014

Lantmännen co-operative association has published a prospectus in relation to an offer to subscribe for participating debentures. The offer, which amounts to a maximum amount of SEK 250 million, is primarily directed to Lantmännen’s members and full-time group employees in Sweden and a number of associations in the agricultural and food industry. Vinge advised Lantmännen in connection with the offer.

Vinge’s team consisted of partner Jesper Schönbeck and associates Joakim Hagberg, Tora Hansjons and Nils Fredrik Dehlin.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025